Company profile: Verseon

1.1 - Company Overview

Verseon

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of an AI- and quantum physics–based drug discovery platform that explores billions of chemical options to identify novel leads; clinical candidate development advancing multiple synthesized and characterized candidates with unique therapeutic profiles; and AI-enabled patient recruitment and trial conduct using a proprietary network for more efficient studies.

Products and services

AI-Driven Drug Discovery: Quantum-informed system combines proprietary AI with quantum physics breakthroughs to identify drugs that could change the standard of care for major diseases
Clinical Candidate Development: Program-level process advances multiple candidates per program with unique therapeutic profiles after synthesis and characterization
Drug Discovery Platform: Computational platform explores billions of chemical options to identify novel drug leads, utilizing AI for optimization

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Verseon

Innate Pharma

HQ: France Website

Description: Provider of first-in-class immunotherapy drug candidates for cancer and inflammatory diseases, specializing in novel monoclonal antibodies and NK cell engagers targeting innate immunity pathways. Pipeline includes ANKET; Lacutamab for cutaneous and peripheral T cell lymphomas; Monalizumab (anti-NKG2A) and CD39 with AstraZeneca for NSCLC and other solid tumors; CD123 and B7-H3 multi-specific ANKETs with Sanofi.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Innate Pharma company profile →

Talecris

HQ: Spain Website

Description: Provider of plasma-derived protein therapies, produced and marketed by a biopharmaceutical company founded in 2004 and based in Barcelona, Spain.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Talecris company profile →

Ascendis Pharma

HQ: United States Website

Description: Provider of the TransCon prodrug technology platform, which transiently conjugates an inert carrier to a parent drug for systemic or localized release, and a pipeline of investigational therapies: TransCon hGH for growth hormone deficiency, TransCon PTH for hypoparathyroidism, TransCon CNP for achondroplasia, and oncology candidates TransCon TLR7/8 Agonist and TransCon IL-2 β/γ.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Ascendis Pharma company profile →

AstraZeneca

HQ: United Kingdom Website

Description: Provider of biopharmaceutical research, development, manufacturing, and marketing of prescription medicines across oncology; cardiovascular, renal and metabolism; respiratory and immunology; vaccines and immune therapies; and rare diseases. Portfolio includes therapies such as datopotamab deruxtecan for advanced nonsquamous non-small cell lung cancer, with clinical trial survival benefits.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full AstraZeneca company profile →

Arch Biopartners

HQ: Canada Website

Description: Provider of product acquisition and development for sale to pharmaceutical and industrial companies, with a focus on LSALT peptide (Metablok), a drug candidate that inhibits DPEP1 to target acute organ inflammation in the lungs, liver, and kidneys, including a Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide for cardiac surgery–associated acute kidney injury.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Arch Biopartners company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Verseon

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Verseon

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Verseon's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Verseon's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Verseon

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Verseon's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Verseon's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Verseon

4.2 - Public trading comparable groups for Verseon

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Verseon

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Verseon

What does Verseon do?

Verseon is a provider of an AI- and quantum physics–based drug discovery platform that explores billions of chemical options to identify novel leads; clinical candidate development advancing multiple synthesized and characterized candidates with unique therapeutic profiles; and AI-enabled patient recruitment and trial conduct using a proprietary network for more efficient studies.

Who are Verseon's competitors?

Verseon's competitors and similar companies include Innate Pharma, Talecris, Ascendis Pharma, AstraZeneca, and Arch Biopartners.

Where is Verseon headquartered?

Verseon is headquartered in United States.

How many employees does Verseon have?

Verseon has 1,000 employees 🔒.

When was Verseon founded?

Verseon was founded in 2010 🔒.

What sector and industry vertical is Verseon in?

Verseon is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Verseon

Who are the top strategic acquirers in Verseon's sector and industry

Top strategic M&A buyers and acquirers in Verseon's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Verseon?

Top strategic M&A buyers groups and sectors for Verseon include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Verseon's sector and industry vertical

Which are the top PE firms investing in Verseon's sector and industry vertical?

Top PE firms investing in Verseon's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Verseon's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Verseon's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Verseon's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Verseon include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Verseon's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Verseon?

The key public trading comparables and valuation benchmarks for Verseon include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Verseon for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Verseon with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Verseon's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Verseon with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Verseon's' sector and industry vertical?

Access recent funding rounds and capital raises in Verseon's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Verseon

Start Free Trial Book a Demo